“The presence of impurities in drug samples is a major concern, not only because some contaminants are inherently toxic, but also because they can affect drug stability and shelf life, or cause unwanted side effects.

There are several pathways by which these elements can be present in pharmaceuticals, for example they can be catalytic elements and other inorganic contaminants that can come through raw materials, the manufacturing process, the environment, packaging materials, and container closure systems.

At Ceimic, we have state-of-the-art equipment that allows us to identify different types of impurities, both organic and inorganic at trace levels, such as metals, in which case the USP 232/233 test by ICP-MS is accredited under ISO 17025.”